We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 151% below its sector, cheaper than its peers on earnings.
Bionime Corporation, headquartered in Taichung, Taiwan, specializes in the development, production, and global distribution of medical instruments. The company maintains a significant international presence, serving markets in countries such as China, Switzerland, the United States, Algeria, and Egypt. Its primary product line features blood glucose monitoring systems, along with essential complementary items like test strips and lancing devices. These healthcare solutions are supplied to a varied customer base, including hospitals, pharmacies, and other medical equipment enterprises. Beyond its core medical device business, Bionime also engages in providing biotechnology-related services, performing pharmaceutical analysis, and marketing high-precision tools. The company was founded in 2003.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 4737.TW and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.